Sotagexal is a beta-blocker. The active substance is sotalol. The medication is available in tablet form and as an injectable solution. Sotagexal tablets have antiarrhythmic, antianginal and antihypertensive activity. The medication promotes sympathetic stimulation in the peripheral vessels, reducing the activity of the renin-angiotensin system.
When taking the drug, the need for myocardial oxygen is reduced by reducing the frequency of contractions, sensitivity to sympathetic innervation. On the basis of arterial hypertension, the effect is noted after 2-5 days. The stable effect of the drug occurs after one to two months of administration.
Appointment
The medicine “Sotagexal” recommends the use of the drug for ventricular tachyarrhythmias (induced and spontaneous), extrasystoles, supraventricular tachycardia. Indications include the paroxysmal form of atrial fibrillation.
Contraindications
Sotagexal is not prescribed (instructions for use warns about this) in case of cardiogenic shock, hypersensitivity, decompensated chronic or acute heart failure, sinus bradycardia. Contraindications include pathologies in the peripheral vessels of the occlusal type, pregnancy, metabolic acidosis, childhood and old age, psoriasis. The drug is not recommended for COPD, arterial hypotension, bronchial asthma, during lactation, with depression, thyrotoxicosis. Do not prescribe a remedy for myasthenia gravis, hypokalemia, or for patients who have had a history of allergic reactions to treatment. Contraindications include diabetes (sugar) with ketoacidosis.
Adverse reactions
Sotagexal medication (instructions for use indicates this) can cause increased fatigue, insomnia or drowsiness, paresthesia in the extremities, tremor, sinus bradycardia. Against the background of therapy, headache, dizziness, memory loss (short-term), confusion, disorders in the peripheral circulation are likely. Undesirable effects include atrioventricular block, arrhythmias, palpitations, visual disturbances, soreness, dry eyes, nasal congestion, keratoconjunctivitis. During therapy with the Sotagexal medication (instructions for use warns about this), gastrointestinal tract disorders, bronchospasm, rhinitis, epigastric and chest pain, orthostatic hypotension, shortness of breath, and taste change are possible. Patients taking the medicine may have an allergic reaction in the form of a rash, burning sensation and other skin manifestations, liver function disorders, hypoglycemia, hypothyroid state, increased sweating.
Dosage regimen
The medication is taken orally. As an antianginal agent, Sotagexal, the instructions for use recommend 80 mg twice a day. The same dosage is the initial for hypertension. If necessary, the amount of funds increases once a week by 80 mg. For other pathologies, dosages are set personally.